Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2020-09-02 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Leflunomide Tablets USP) by Lupin Limited, including details about FDA approval and product information. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory disclosure of a corporate event (product launch) rather than a financial report or earnings release. The document length is 4038 characters, which is relatively short and consistent with a press release or regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like earnings release or annual report.
2020-09-02 English
Lupin and Mylan Launch Nepexto®, Biosimilar Etanercept in Germany.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the launch of Nepexto®, a biosimilar etanercept, in the German market by Lupin Limited and Mylan N.V. It contains no financial statements, regulatory filings, or detailed financial data. The content focuses on product launch information, regulatory approval, and market introduction. It is not an annual report, earnings release, management report, or any other financial or regulatory filing. The document is a corporate announcement intended for public and investor information about a new product launch, fitting the definition of a Capital/Financing Update as it relates to a significant business development impacting the company's market activities and product portfolio.
2020-08-26 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated August 26, 2020, announcing the launch of Nepexto®, a biosimilar etanercept, in the German market by Lupin Limited and Mylan N.V. It includes detailed product information, regulatory approval details, and quotes from company executives. The document is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. It does not contain financial statements, management discussion, or detailed financial data. It is not an earnings release, annual report, or interim report. It is a corporate announcement about a product launch and regulatory approval, fitting the category of a Capital/Financing Update or general corporate disclosure. However, since it is primarily a product launch announcement and regulatory disclosure under SEBI Listing Obligations, it best fits under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2020-08-26 English
Disclosure in respect of allotment of 13316 shares under ESOP.
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the allotment of shares under the Employee Stock Option Plan (ESOP). It announces the allotment of 13,316 fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The document is a formal announcement to the stock exchange and does not contain financial statements or detailed financial analysis. It is a notification about a capital change due to share allotment under ESOP, which fits the category of Share Issue/Capital Change (SHA). The document length is short (1729 characters), and it is not a report or a certification but an announcement of a capital change event.
2020-08-25 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure to the National Stock Exchange of India regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It mentions the allotment of fully paid-up equity shares and the resulting increase in issued and paid-up capital. The document is a notification of a capital change due to share allotment, not a full financial report or earnings release. It is not an announcement of a report publication but a direct update on share capital changes. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and focused solely on this capital change, confirming the classification.
2020-08-25 English
Lupin Receives Approval for Generic Albuterol Sulphate MDI.
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the receipt of U.S. FDA approval for a generic pharmaceutical product by Lupin Limited. It is addressed to stock exchanges and references regulatory disclosure requirements (SEBI Regulation 30). The content focuses on the approval event and product details, not on financial results, management changes, or detailed financial data. It is not an earnings release or annual/interim report. It is a corporate announcement about a significant business development. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, and also significant corporate announcements related to business operations and approvals. Confidence is high given the clear nature of the announcement and its regulatory disclosure context.
2020-08-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.